Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial.

Bjermer Leif Isabelle H Boucot Claus F Vogelmeier Francois Maltais Paul W JonesLee TombsChris ComptonDavid A Lipson Edward M Kerwin

Published in: Advances in therapy (2021)

In current and former smokers, umeclidinium/vilanterol provided greater improvements in lung function and symptoms versus umeclidinium and salmeterol, supporting consideration of dual-bronchodilator therapy in symptomatic patients with COPD regardless of their smoking status.

Keyphrases

lung function
smoking cessation
chronic obstructive pulmonary disease
cystic fibrosis
air pollution
replacement therapy
clinical trial
study protocol
phase iii
phase ii
randomized controlled trial
sleep quality
open label